Tim Noah Kempchen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tim Noah Kempchen has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Michael Hölzel
Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany
6 shared publications - Alexander Hoch
Institute for Clinical Chemistry and Clinical Pharmacology, University of Bonn, University Hospital Bonn, Bonn, Germany
4 shared publications - Tobias Bald
Institute for Experimental Oncology, University Hospital Bonn, 53127 Bonn, Germany
4 shared publications - Benjamin A. McEnroe
Institute for Experimental Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany
3 shared publications - Bianca Broske
Institute for Experimental Oncology, University of Bonn, University Hospital Bonn, Bonn, Germany
3 shared publications - Dominic Ferber
Institute of Structural Biology, University of Bonn, Venusberg Campus 1, 53127 Bonn, Germany
3 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8736
AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins
Experimental validation and functional optimization remain bottlenecks in AI-based protein design. We present a scalable workflow for developing AI-designed minibinders against cancer-associated surface proteins. Screening thousands of designs using mammalian cell-surface display identifies several high-affinity PD-L1 minibinders but far fewer for CD276 (B7-H3) and VTCN1 (B7-H4), highlighting substantial target dependence. Interface predicted template modeling (ipTM) scores generated by Chai-1 with ESM embeddings correlate with binding success and capture deleterious effects of interface mutations. Fluorophore-labeled AI-minibinders enable flow-cytometric staining comparable to conventional antibodies. However, when incorporated into chimeric antigen receptors (CAR), some show poor cell-surface trafficking and limited functionality. Redesign through a genetic algorithm-based diversification strategy that preserves the binding interface while changing non-binding surfaces experimentally reveals an isoelectric point (pI) window that improves CAR expression and enhances target-selective tumor cell killing. Our findings identify biochemical optimization beyond the binding interface as a critical requirement for translating AI-minibinders into functional applications.
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8736
Open AccessAI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins
Experimental validation and functional optimization remain bottlenecks in AI-based protein design. We present a scalable workflow for developing AI-designed minibinders against cancer-associated surface proteins. Screening thousands of designs using mammalian cell-surface display identifies several high-affinity PD-L1 minibinders but far fewer for CD276 (B7-H3) and VTCN1 (B7-H4), highlighting substantial target dependence. Interface predicted template modeling (ipTM) scores generated by Chai-1 with ESM embeddings correlate with binding success and capture deleterious effects of interface mutations. Fluorophore-labeled AI-minibinders enable flow-cytometric staining comparable to conventional antibodies. However, when incorporated into chimeric antigen receptors (CAR), some show poor cell-surface trafficking and limited functionality. Redesign through a genetic algorithm-based diversification strategy that preserves the binding interface while changing non-binding surfaces experimentally reveals an isoelectric point (pI) window that improves CAR expression and enhances target-selective tumor cell killing. Our findings identify biochemical optimization beyond the binding interface as a critical requirement for translating AI-minibinders into functional applications.
- Open Access
Evolutionary algorithms accelerate de novo design of potent Nectin-4-specific cancer biologics
Recent advances in AI-based structural biology have made de novo protein binder design increasingly effective, yet performance remains highly target dependent. For instance, the cancer surface antigen Nectin-4, an immunoglobulin-like cell adhesion protein, proved particularly challenging for RFdiffusion-based minibinder generation, yielding substantially fewer high-quality candidates than related targets. To address this bottleneck, we integrated an evolutionary genetic algorithm (GA) with AI-driven design. GA selection with tunable stringency was coupled with diversification via partial diffusion or direct sequence editing, enabling efficient exploration of sequence-structure space and rapid enrichment of promising candidates. This AI-GA pipeline quickly produced large and diverse minibinder panels with very good in silico quality metrics and is compatible with inputs from multiple design algorithms. Pooled, large-scale experimental screening identified highly stable Nectin-4 minibinders with single-digit nanomolar down to subnanomolar affinities. Lead binders were further engineered into Nectin-4-specific flow cytometry detection reagents and potent bispecific T cell engagers, demonstrating functional activity beyond binding. Together, these results show that evolutionary refinement can unlock challenging targets and accelerate de novo protein design for next-generation cancer biologics.
Open AccessEvolutionary algorithms accelerate de novo design of potent Nectin-4-specific cancer biologics
Recent advances in AI-based structural biology have made de novo protein binder design increasingly effective, yet performance remains highly target dependent. For instance, the cancer surface antigen Nectin-4, an immunoglobulin-like cell adhesion protein, proved particularly challenging for RFdiffusion-based minibinder generation, yielding substantially fewer high-quality candidates than related targets. To address this bottleneck, we integrated an evolutionary genetic algorithm (GA) with AI-driven design. GA selection with tunable stringency was coupled with diversification via partial diffusion or direct sequence editing, enabling efficient exploration of sequence-structure space and rapid enrichment of promising candidates. This AI-GA pipeline quickly produced large and diverse minibinder panels with very good in silico quality metrics and is compatible with inputs from multiple design algorithms. Pooled, large-scale experimental screening identified highly stable Nectin-4 minibinders with single-digit nanomolar down to subnanomolar affinities. Lead binders were further engineered into Nectin-4-specific flow cytometry detection reagents and potent bispecific T cell engagers, demonstrating functional activity beyond binding. Together, these results show that evolutionary refinement can unlock challenging targets and accelerate de novo protein design for next-generation cancer biologics.
- Open Access
- 27 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10652
SPACEc: a streamlined, interactive Python workflow for multiplexed image processing and analysis
Multiplexed imaging has transformed our ability to study tissue organization by capturing thousands of cells and molecules in their native context. However, these datasets are enormous, often comprising tens of gigabytes per image, and require complex workflows that limit their broader use. Current tools are often fragmented, inefficient, and difficult to adopt across disciplines. Here we show that SPACEc, a scalable Python platform, streamlines spatial imaging analysis from start to finish. The platform integrates image processing, cell segmentation, and data preprocessing into a single workflow, while improving computational performance through parallelization and GPU acceleration. We introduce innovative methods, including patch proximity analysis, to more accurately map local cellular neighborhoods and interactions. SPACEc also simplifies advanced approaches such as deep-learning annotation, making them accessible through an intuitive interface. By combining efficiency, accuracy, and usability, this platform enables researchers from diverse backgrounds to gain deeper insights into tissue architecture and cellular microenvironments.
- 27 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10652
Open AccessSPACEc: a streamlined, interactive Python workflow for multiplexed image processing and analysis
Multiplexed imaging has transformed our ability to study tissue organization by capturing thousands of cells and molecules in their native context. However, these datasets are enormous, often comprising tens of gigabytes per image, and require complex workflows that limit their broader use. Current tools are often fragmented, inefficient, and difficult to adopt across disciplines. Here we show that SPACEc, a scalable Python platform, streamlines spatial imaging analysis from start to finish. The platform integrates image processing, cell segmentation, and data preprocessing into a single workflow, while improving computational performance through parallelization and GPU acceleration. We introduce innovative methods, including patch proximity analysis, to more accurately map local cellular neighborhoods and interactions. SPACEc also simplifies advanced approaches such as deep-learning annotation, making them accessible through an intuitive interface. By combining efficiency, accuracy, and usability, this platform enables researchers from diverse backgrounds to gain deeper insights into tissue architecture and cellular microenvironments.
- 20 November 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 106 (1) , 104262
Comparative Evaluation of Antibody-Oligonucleotide Conjugation Strategies for Multiplexed Imaging Applications
- 20 November 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 106 (1) , 104262
Comparative Evaluation of Antibody-Oligonucleotide Conjugation Strategies for Multiplexed Imaging Applications
- Open Access
Low-branching vessel architecture shapes immune cell niches and predicts immune responses in renal cancer
Clear cell renal cell carcinoma (ccRCC) is characterized by marked histological heterogeneity, encompassing its vasculature. Here, we introduce PropSegNet, a learning-based algorithm that segments and classifies three distinct vascular patterns in CD31-stained tissue sections. Integrating transcriptomic features, our work identifies a trajectory from high- to low-branching vessel architecture that co-evolves with the loss of proximal tubular cell traits in tumor cells. Furthermore, low-branching vessels form niches enriched with T cells and antigen-presenting cells. Mechanistically, air-liquid-interface cultures of patient-derived tumor fragments confirm that low-branching vessel features associate with T cell infiltration resulting in reduced viability under IL-2 rich conditions. Post-hoc transcriptomic analyses from two phase III clinical trials demonstrate that patients with tumors exhibiting an inflamed, low-branching vascular phenotype benefit most from the addition of immune checkpoint inhibition to anti-angiogenic treatment. These findings provide a rationale for prospective evaluation of vascular patterns and vessel-immune cell niches as potential biomarkers in ccRCC.
Open AccessLow-branching vessel architecture shapes immune cell niches and predicts immune responses in renal cancer
Clear cell renal cell carcinoma (ccRCC) is characterized by marked histological heterogeneity, encompassing its vasculature. Here, we introduce PropSegNet, a learning-based algorithm that segments and classifies three distinct vascular patterns in CD31-stained tissue sections. Integrating transcriptomic features, our work identifies a trajectory from high- to low-branching vessel architecture that co-evolves with the loss of proximal tubular cell traits in tumor cells. Furthermore, low-branching vessels form niches enriched with T cells and antigen-presenting cells. Mechanistically, air-liquid-interface cultures of patient-derived tumor fragments confirm that low-branching vessel features associate with T cell infiltration resulting in reduced viability under IL-2 rich conditions. Post-hoc transcriptomic analyses from two phase III clinical trials demonstrate that patients with tumors exhibiting an inflamed, low-branching vascular phenotype benefit most from the addition of immune checkpoint inhibition to anti-angiogenic treatment. These findings provide a rationale for prospective evaluation of vascular patterns and vessel-immune cell niches as potential biomarkers in ccRCC.
- Open Access
Transposon-Display of AI-designed binders enables manipulation of the proteome in human cells
Transposon-Display is a highly scalable screening method that links proteins to their encoding DNA during expression in E. coli via a mutant transposase. Leveraging this system, we identified AI-designed binders targeting four intracellular human proteins, saturation-mutagenized top candidates, and charge-balanced variants to improve compatibility with the intracellular environment while preserving target binding. The resulting neutral binders can be fused to EGFP allowing antibody-free intracellular staining. Expressing neutral binders in human cells as fusions with functional domains can drive small molecule-controlled protein aggregation and trigger proteasomal degradation of endogenous target proteins in living cells. Manipulating the proteome of living cells using libraries of AI-designed binders may provide a new avenue to screen for disease-relevant protein functions and large-scale functional data may help to refine protein design algorithms.
Open AccessTransposon-Display of AI-designed binders enables manipulation of the proteome in human cells
Transposon-Display is a highly scalable screening method that links proteins to their encoding DNA during expression in E. coli via a mutant transposase. Leveraging this system, we identified AI-designed binders targeting four intracellular human proteins, saturation-mutagenized top candidates, and charge-balanced variants to improve compatibility with the intracellular environment while preserving target binding. The resulting neutral binders can be fused to EGFP allowing antibody-free intracellular staining. Expressing neutral binders in human cells as fusions with functional domains can drive small molecule-controlled protein aggregation and trigger proteasomal degradation of endogenous target proteins in living cells. Manipulating the proteome of living cells using libraries of AI-designed binders may provide a new avenue to screen for disease-relevant protein functions and large-scale functional data may help to refine protein design algorithms.
- Open Access
Development of AI-designed protein binders for detection and targeting of cancer cell surface proteins
Artificial intelligence (AI)-based protein design opens new avenues for the rapid generation of new research tools and therapeutics, but experimental validation lags behind the computational design throughput. Here, we present a scalable workflow for the discovery and validation of AI-designed protein binders. Leveraging the RFdiffusion protein design pipeline with a custom filter for stable alpha-helical bundle folds, we construct libraries of thousands of AI-binders against cancer-associated surface proteins. Mammalian cell-surface and phage display screening yield multiple high-affinity PD-L1 binders but fewer hits for CD276 (B7-H3) and VTCN1 (B7-H4), reflecting the target-dependent efficiency of RFdiffusion in generating high-quality designs. Using our experimentally validated AI-designed binder libraries, we benchmark freely available structure prediction models. We find that interface predicted template modelling (ipTM) scores by Chai-1 with ESM embedding correlate well with experimental success and even predict deleterious effects of binding interface mutations. To demonstrate the versatility of AI-binders as research tools, we deploy them in CAR-T cells and also assemble them with fluorophore-labeled streptavidin into tetravalent quattrobinders, which achieve antibody-comparable staining of endogenous PD-L1 by flow cytometry. With high production yields and accessible structural models, AI-designed quattrobinders are versatile and cost-effective research tools amenable to community-driven validation and optimization.
Open AccessDevelopment of AI-designed protein binders for detection and targeting of cancer cell surface proteins
Artificial intelligence (AI)-based protein design opens new avenues for the rapid generation of new research tools and therapeutics, but experimental validation lags behind the computational design throughput. Here, we present a scalable workflow for the discovery and validation of AI-designed protein binders. Leveraging the RFdiffusion protein design pipeline with a custom filter for stable alpha-helical bundle folds, we construct libraries of thousands of AI-binders against cancer-associated surface proteins. Mammalian cell-surface and phage display screening yield multiple high-affinity PD-L1 binders but fewer hits for CD276 (B7-H3) and VTCN1 (B7-H4), reflecting the target-dependent efficiency of RFdiffusion in generating high-quality designs. Using our experimentally validated AI-designed binder libraries, we benchmark freely available structure prediction models. We find that interface predicted template modelling (ipTM) scores by Chai-1 with ESM embedding correlate well with experimental success and even predict deleterious effects of binding interface mutations. To demonstrate the versatility of AI-binders as research tools, we deploy them in CAR-T cells and also assemble them with fluorophore-labeled streptavidin into tetravalent quattrobinders, which achieve antibody-comparable staining of endogenous PD-L1 by flow cytometry. With high production yields and accessible structural models, AI-designed quattrobinders are versatile and cost-effective research tools amenable to community-driven validation and optimization.
- Open Access
- 12 November 2024
- Published by Wiley in European Journal of Immunology
- Vol. 55 (1) , e202451371
Type I Interferon Drives a Cellular State Inert to TCR‐Stimulation and Could Impede Effective T‐Cell Differentiation in Cancer
Background: Head and neck squamous cell carcinoma (HNSCC) is linked to human papillomavirus (HPV) infection. HPV‐positive and HPV‐negative HNSCC exhibit distinct molecular and clinical characteristics. Although checkpoint inhibitors have shown efficiency in recurrent/metastatic HNSCC, response variability persists regardless of HPV status. This study aimed to explore the CD8+ T‐cell landscape in HPV‐negative HNSCC.Methods: We performed simultaneous single‐cell RNA and TCR sequencing of CD8+ tumor‐infiltrating lymphocytes (TILs) from treatment‐naïve HPV‐negative HNSCC patients. Additionally, cells were stimulated ex vivo, which allowed for the tracking of clonal transcriptomic responses.Results: Our analysis identified a subset of CD8+ TILs highly enriched for interferon‐stimulated genes (ISG). TCR analysis revealed ISG cells are clonally related to a population of granzyme K (GZMK)‐expressing cells. However, unlike GZMK cells, which exhibited rapid effector‐like phenotypes following stimulation, ISG cells were transcriptionally inert. Additionally, ISG cells showed specific enrichment within tumor and were found across multiple tumor entities.Conclusions: ISG‐enriched CD8+ TILs are a consistent feature of various tumor entities. These cells are poorly understood but possess characteristics that may impact antitumor immunity. Understanding the unique properties and functionality of ISG cells could offer innovative treatment approaches to improve patient outcomes in HPV‐negative HNSCC and other cancer types.
- 12 November 2024
- Published by Wiley in European Journal of Immunology
- Vol. 55 (1) , e202451371
Open AccessType I Interferon Drives a Cellular State Inert to TCR‐Stimulation and Could Impede Effective T‐Cell Differentiation in Cancer
Background: Head and neck squamous cell carcinoma (HNSCC) is linked to human papillomavirus (HPV) infection. HPV‐positive and HPV‐negative HNSCC exhibit distinct molecular and clinical characteristics. Although checkpoint inhibitors have shown efficiency in recurrent/metastatic HNSCC, response variability persists regardless of HPV status. This study aimed to explore the CD8+ T‐cell landscape in HPV‐negative HNSCC.Methods: We performed simultaneous single‐cell RNA and TCR sequencing of CD8+ tumor‐infiltrating lymphocytes (TILs) from treatment‐naïve HPV‐negative HNSCC patients. Additionally, cells were stimulated ex vivo, which allowed for the tracking of clonal transcriptomic responses.Results: Our analysis identified a subset of CD8+ TILs highly enriched for interferon‐stimulated genes (ISG). TCR analysis revealed ISG cells are clonally related to a population of granzyme K (GZMK)‐expressing cells. However, unlike GZMK cells, which exhibited rapid effector‐like phenotypes following stimulation, ISG cells were transcriptionally inert. Additionally, ISG cells showed specific enrichment within tumor and were found across multiple tumor entities.Conclusions: ISG‐enriched CD8+ TILs are a consistent feature of various tumor entities. These cells are poorly understood but possess characteristics that may impact antitumor immunity. Understanding the unique properties and functionality of ISG cells could offer innovative treatment approaches to improve patient outcomes in HPV‐negative HNSCC and other cancer types.